Nanoparticle Surface Engineering
LNP Architecture
Therapeutic Preset
Targeting Ligand
anti-EGFR
Surface antibodies/peptides bind specific receptors on tumor cells and tumor-associated macrophages (TAMs).
PEG Shielding Density
75%
High PEG density prevents protein corona formation and MPS/liver clearance, extending circulation half-life.
Zeta Surface Charge
-12 mV
Slightly negative charge avoids lung thrombosis, while switchable pH-dependent charge enables endosomal escape in tumors.
mRNA Therapeutic Payload
Cellular Reprogramming Mechanism
Tumors corrupt macrophages into immune-suppressive M2 cells that guard malignancy. These smart LNPs penetrate porous tumor vasculature, deliver transcript instructions, and rearm corrupted immune sentries into active cytotoxic hunters.
Smart mRNA LNP
Corrupted M2 Macrophage
Reprogrammed M1 Killer
Malignant Tumor Cell
CD8+ Cytotoxic T-Cell
Trial Telemetry & Efficacy
Real-time Assay
Optimal Reprogramming Achieved
DELIVERY EFFICIENCY
▲ Active Extravasation
88.4%
IMMUNE REPROGRAMMING
★ M2 → M1 Conversion
92.1%
TUMOR REGRESSION RATE
Shrinkage Velocity
76.5%
OFF-TARGET ACCUMULATION
▼ MPS/Liver Sequestration
4.2%
Live Microenvironment Event Log
[00:00] Capillary microcirculation initialized.
[00:01] 24 smart LNPs injected into blood flow.
[00:02] Anti-EGFR ligand engagement at tumor border.
[00:03] TAM Endosomal mRNA release confirmed.